CATB - Catabasis Pharmaceuticals - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

with an average price target of $18.46. This is a potential upside of $18.46 (0%) from yesterday's end of day stock price of $0.

Catabasis Pharmaceuticals's activity chart (see below) currently has 10 price targets and 18 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 36.11% with an average time for these price targets to be met of 150 days.

Most recent stock forecast was given by HARTAJ SINGH from OPPENHEIMER on 11-Mar-2021. First documented stock forecast 20-Jul-2015.

Best performing analysts who are covering CATB - Catabasis Pharmaceuticals:

Hartaj Singh Liana Moussatos Joel Beatty

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$30

$22.93 (324.33%)

3 years 8 months 25 days ago
(11-Mar-2021)

1/3 (33.33%)

$9.24 (44.51%)

63

Buy

$6.9

$-0.17 (-2.40%)

$90

4 years 1 months 4 days ago
(02-Nov-2020)

1/4 (25%)

$-1.26 (-15.44%)

350

Buy

$150

$142.93 (2021.64%)

7 years 16 days ago
(20-Nov-2017)

1/2 (50%)

$47.4 (46.20%)

37

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CATB (Catabasis Pharmaceuticals) average time for price targets to be met?

On average it took 150 days on average for the stock forecasts to be realized with a an average price target met ratio 36.11

Which analyst has the current highest performing score on CATB (Catabasis Pharmaceuticals) with a proven track record?

HARTAJ SINGH

Which analyst has the current lower performing score on CATB (Catabasis Pharmaceuticals) with a proven track record?

JOEL BEATTY

Which analyst has the most public recommendations on CATB (Catabasis Pharmaceuticals)?

Hartaj Singh works at OPPENHEIMER and has 24 price targets and 12 ratings on CATB

Which analyst is the currently most bullish on CATB (Catabasis Pharmaceuticals)?

Joel Beatty with highest potential upside - $142.93

Which analyst is the currently most reserved on CATB (Catabasis Pharmaceuticals)?

Liana Moussatos with lowest potential downside - -$0.17

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?